| 1. |
- Oltmanns, Carlos, et al.
(author)
-
Elevation of S2-bound a1-acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma
- 2024
-
In: Journal of Viral Hepatitis. - : WILEY. - 1352-0504 .- 1365-2893.
-
Journal article (peer-reviewed)abstract
- There is an urgent need for new high-quality markers for the early detection of hepatocellular carcinoma (HCC). angstrom strom et al. suggested that S2-bound alpha 1-acid glycoprotein (AGP) might be a promising marker. Consequently, we evaluated the predictive advantage of S2-bound AGP in the early detection of HCC. In a retrospective case-control study of patients chronically infected with hepatitis C virus (HCV) and treated with direct-acting antiviral agents (n = 93), we measured S2-bound AGP using the HepaCheC (R) ELISA kit (Glycobond AB, Linkoping, SE) at the start of treatment, end of treatment and follow-up (maximum: 78 months). Patients were retrospectively propensity score matched (1:2). Thirty-one patients chronically infected with HCV developed HCC after a sustained virological response, while 62 did not. In addition, samples of patients with chronic hepatitis B virus infection, metabolic dysfunction-associated steatotic liver disease and HCC of different etiologies were analysed. S2-bound AGP elevation in HCC patients was confirmed. However, we did not observe a predictive advantage of S2-bound AGP for the early detection of HCC during treatment and follow-up. Interestingly, S2-bound AGP levels correlated with aspartate aminotransferase (rho = .56, p = 9.5x10-15) and liver elastography (rho = .67, p = 2.2x10-16). Of note, S2-bound AGP decreased in patients chronically infected with HCV after treatment-induced HCV clearance. Fucosylated S2-bound AGP levels were elevated in patients with chronic HCV and HCC. The potential role of S2-bound AGP as a novel tumour marker requires further investigation.
|
|
